A 66-year-old woman from Myanmar underwent a liver transplant surgery at a private hospital in the city.

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

Immunotherapy, a form of treatment that uses the body’s immune system to find and fight cancer cells, can delay the ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...